Macrocure Ltd. Or Sh (MCUR) 1.45 $MCUR
Macrocure Stock Up on Merger Deal with Leap Therapeutics
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:05AM CDT
Macrocure Ltd. (MCUR) announced that it has signed a definitive merger agreement with the privately held company, Leap Therapeutics, Inc.
ANIP: 66.64 (-0.17), MCUR: 1.45 (+0.03), LLY: 81.16 (-0.13), ANIK: 46.92 (-1.07)
Leap Therapeutics and Macrocure Announce Definitive Merger Agreement
PR Newswire - Mon Aug 29, 7:51AM CDT
Leap Therapeutics, Inc., a clinical stage immuno-oncology company, and Macrocure Ltd. (NASDAQ: MCUR) today announced the signing of a definitive merger agreement. Under the terms of the agreement, Macrocure will become a wholly owned subsidiary of Leap, and Leap will become a public company. In connection with the transaction, Leap will apply to have the shares of the combined entity listed for trading on NASDAQ upon completion of the merger.
MCUR: 1.45 (+0.03)
These Four Emerging Companies Deserve a Look
PR Newswire - Mon Jun 20, 10:34AM CDT
DailyStockReporter.com Briefing: LifeClips Inc. (OTC: LCLP) (OTCQB: LCLP) has been gaining a lot of attention over the weekend following several reports from social financial sites like Investors Hub, that the company's newly acquired company, Batterfly Energy, has its Mobeego product already placed in high profile outlets like in the US like the MGM Grand Hotel's "Grand & Co." (http://bit.ly/24ZMEm5)
MCUR: 1.45 (+0.03), LPTN: 3.89 (+0.29), NVCN: 0.56 (+0.02)
Stocks To Watch: Investors Are Considering These on Monday April 25th
ACCESSWIRE - Mon Apr 25, 10:31AM CDT
MIAMI, FL / ACCESSWIRE / April 25, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. NEOT, MCUR, TPUB, and LGCY have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
LGCY: 1.39 (-0.06), TPUB: 13.96 (+0.17), MCUR: 1.45 (+0.03), NEOT: 1.22 (-0.03)
Macrocure Files Annual Report on Form 20-F for the Year Ended December 31, 2015
PR Newswire - Wed Apr 20, 6:00AM CDT
Macrocure Ltd. (NASDAQ: MCUR) ("Macrocure" or the "Company"
, a clinical-stage biotechnology company, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2015 with the U.S. Securities and Exchange Commission (the "SEC" . The annual report on Form 20-F, which contains Macrocure's audited financial statements, can be accessed on the SEC's website at http://www.sec.gov, as well as via the Company's investor relations website at http://investor.macrocure.com/annuals-proxies.cfm. The Company will deliver a hard copy of its annual report on Form 20-F, including its complete audited financial statements, free of charge, to its shareholders upon request to Shai Lankry, the Company's Chief Financial Officer, at +972-3-923-5556, or Shai@Macrocure.com.
MCUR: 1.45 (+0.03)
Macrocure Announces Annual General Meeting of Shareholders
GlobeNewswire - Wed Dec 09, 8:26AM CST
Macrocure Ltd. (NASDAQ:MCUR), a clinical-stage biotechnology company, today announced that it will hold its Annual General Meeting of Shareholders on Wednesday, January 13, 2016, at 3:00 p.m., Israel time (8:00 a.m. EST). The record date for shareholders entitled to vote at the annual meeting is Monday, December 14, 2015.
MCUR: 1.45 (+0.03)
Ford and Vale are big market movers
AP - Mon Nov 30, 3:26PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq stock market:
SPLS: 8.54 (-0.01), F: 12.17 (-0.01), CSC: 51.57 (-0.30), ORMP: 7.84 (-0.03), VALE: 5.42 (unch), MCUR: 1.45 (+0.03), ODP: 3.71 (+0.08)
Macrocure Ltd. Reports Changes to Senior Management and the Board of Directors
GlobeNewswire - Fri Nov 27, 12:05PM CST
Macrocure Ltd. ("Macrocure" or the "Company" (NASDAQ:MCUR), today announced that as the Company continues to explore potential strategic alternatives, Tomer Kariv, a current Director on the Company's Board and CEO & Founder of Pontifax, will become Chairman of the Board replacing David Ben-Ami, current Chairman of the Company's Board of Directors, who will remain a member of Macrocure's Board of Directors. Mark Page, Chief Financial Officer, will be stepping down from his position at Macrocure by February 2016 to pursue other opportunities. Shai Lankry, current VP Finance and former CFO of Macrocure, will be assuming Mark's responsibilities. Dr. Michael Molyneaux, Chief Medical Officer, will also step down from his position in December.
MCUR: 1.45 (+0.03)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Mon Nov 23, 10:33AM CST
NEW YORK, NY / ACCESSWIRE / November 23rd, 2015 / StockMarketLeader.com is an investor alert service that exclusively highlights public companies on the NASDAQ & NYSE with strong upside potential. We are committed to providing the best recommendations in the market on a short and long term basis. Receive our free trade alerts via text message (SMS) and/or email at www.StockMarketLeader.com. Today we are focusing on four companies to watch trading under $500M Market Cap that have been attracting major attention in the market.
SUNE: 0.34 (unch), MCUR: 1.45 (+0.03)
Macrocure Ltd. Reports Third Quarter 2015 Financial Results
GlobeNewswire - Tue Nov 17, 3:05PM CST
Macrocure Ltd. ("Macrocure" or the "Company" (NASDAQ:MCUR), today provided a corporate update and reported financial results for the third quarter and nine months ended September 30, 2015.
MCUR: 1.45 (+0.03)
Macrocure Ltd. Announces Results for Phase III Clinical Trial of CureXcell(R) in Diabetic Foot Ulcers and Provides Corporate Update
GlobeNewswire - Tue Oct 27, 4:20PM CDT
Macrocure Ltd. ("Macrocure" or the "Company" (NASDAQ:MCUR), a clinical-stage biotechnology company focused on advancing its novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that results from a pivotal Phase 3 multicenter, randomized, double-blind, parallel-group, sham-controlled study (MC-102) of CureXcell(R) in the treatment of diabetic foot ulcers (DFUs) did not meet its primary endpoint. CureXcell, the Company's lead product candidate, did not show a statistically significant proportion of subjects with complete closure at 16 weeks and sustained complete closure for four additional weeks. In addition, CureXcell did not meet the secondary endpoints of the study.
MCUR: 1.45 (+0.03)
Moving Average Crossover Alert: Macrocure (MCUR)
Zacks Equity Research - Zacks Investment Research - Mon Sep 21, 8:40AM CDT
Moving Average Crossover Alert: Macrocure (MCUR)
MCUR: 1.45 (+0.03)
Second Quarter Results at a Glance - Report on Macrocure Ltd.
PR Newswire - Wed Sep 16, 8:25AM CDT
ACI Association has initiated research coverage on Macrocure Ltd. (NASDAQ: MCUR). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
MCUR: 1.45 (+0.03)
Macrocure Ltd. Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell(R) in Venous Leg Ulcers
GlobeNewswire - Wed Aug 19, 5:40PM CDT
Macrocure Ltd. ("Macrocure" or the "Company" (NASDAQ:MCUR), a clinical-stage biotechnology company focused on advancing its novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that a pre-specified, futility analysis conducted by the Data Safety Monitoring Board for CureXcell(R) - the Company's lead product candidate in its Phase 3 pivotal clinical study (MC-105) for venous leg ulcers (VLU) - determined that this study is not expected to meet its primary endpoint.
MCUR: 1.45 (+0.03)
Macrocure Ltd. Provides Corporate Update and Reports Second Quarter 2015 Financial Results
GlobeNewswire - Tue Aug 04, 3:05PM CDT
--Company to Report VLU Futility Analysis Results in the Second Half of August 2015--
MCUR: 1.45 (+0.03)
Macrocure Ltd. Announces Second Quarter 2015 Financial Results Date and Conference Call
GlobeNewswire - Wed Jul 22, 7:01AM CDT
Macrocure Ltd. (NASDAQ:MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, will announce financial results for the second quarter ended June 30, 2015 after the close of the U.S. financial markets on Tuesday, August 4, 2015. An accompanying conference call to discuss the financial results and provide a business update will be held on Wednesday, August 5, 2015 at 9:00 am ET; 6:00 am PT; 4:00 pm Israel time.
MCUR: 1.45 (+0.03)
Macrocure (MCUR) Falls: Stock Goes Down 10% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 24, 7:41AM CDT
Macrocure fell nearly 10% in the last trading session, reversing its recent uptrend
GILD: 81.37 (-0.15), MCUR: 1.45 (+0.03)
Macrocure Ltd. to Present at the Jefferies 2015 Global Healthcare Conference
GlobeNewswire - Fri May 29, 7:00AM CDT
Macrocure Ltd. (Nasdaq:MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that at 10:30 AM ET on Thursday, June 4, 2015, Mr. Nissim Mashiach, Macrocure's President and Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference in New York City.
MCUR: 1.45 (+0.03)
Macrocure Stock Up on Merger Deal with Leap Therapeutics
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:05AM CDT
Macrocure Ltd. (MCUR) announced that it has signed a definitive merger agreement with the privately held company, Leap Therapeutics, Inc.
ANIP: 66.64 (-0.17), MCUR: 1.45 (+0.03), LLY: 81.16 (-0.13), ANIK: 46.92 (-1.07)
Leap Therapeutics and Macrocure Announce Definitive Merger Agreement
PR Newswire - Mon Aug 29, 7:51AM CDT
Leap Therapeutics, Inc., a clinical stage immuno-oncology company, and Macrocure Ltd. (NASDAQ: MCUR) today announced the signing of a definitive merger agreement. Under the terms of the agreement, Macrocure will become a wholly owned subsidiary of Leap, and Leap will become a public company. In connection with the transaction, Leap will apply to have the shares of the combined entity listed for trading on NASDAQ upon completion of the merger.
MCUR: 1.45 (+0.03)
These Four Emerging Companies Deserve a Look
PR Newswire - Mon Jun 20, 10:34AM CDT
DailyStockReporter.com Briefing: LifeClips Inc. (OTC: LCLP) (OTCQB: LCLP) has been gaining a lot of attention over the weekend following several reports from social financial sites like Investors Hub, that the company's newly acquired company, Batterfly Energy, has its Mobeego product already placed in high profile outlets like in the US like the MGM Grand Hotel's "Grand & Co." (http://bit.ly/24ZMEm5)
MCUR: 1.45 (+0.03), LPTN: 3.89 (+0.29), NVCN: 0.56 (+0.02)
Stocks To Watch: Investors Are Considering These on Monday April 25th
ACCESSWIRE - Mon Apr 25, 10:31AM CDT
MIAMI, FL / ACCESSWIRE / April 25, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. NEOT, MCUR, TPUB, and LGCY have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
LGCY: 1.39 (-0.06), TPUB: 13.96 (+0.17), MCUR: 1.45 (+0.03), NEOT: 1.22 (-0.03)
Macrocure Files Annual Report on Form 20-F for the Year Ended December 31, 2015
PR Newswire - Wed Apr 20, 6:00AM CDT
Macrocure Ltd. (NASDAQ: MCUR) ("Macrocure" or the "Company"
, a clinical-stage biotechnology company, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2015 with the U.S. Securities and Exchange Commission (the "SEC" . The annual report on Form 20-F, which contains Macrocure's audited financial statements, can be accessed on the SEC's website at http://www.sec.gov, as well as via the Company's investor relations website at http://investor.macrocure.com/annuals-proxies.cfm. The Company will deliver a hard copy of its annual report on Form 20-F, including its complete audited financial statements, free of charge, to its shareholders upon request to Shai Lankry, the Company's Chief Financial Officer, at +972-3-923-5556, or Shai@Macrocure.com. MCUR: 1.45 (+0.03)
Macrocure Announces Annual General Meeting of Shareholders
GlobeNewswire - Wed Dec 09, 8:26AM CST
Macrocure Ltd. (NASDAQ:MCUR), a clinical-stage biotechnology company, today announced that it will hold its Annual General Meeting of Shareholders on Wednesday, January 13, 2016, at 3:00 p.m., Israel time (8:00 a.m. EST). The record date for shareholders entitled to vote at the annual meeting is Monday, December 14, 2015.
MCUR: 1.45 (+0.03)
Ford and Vale are big market movers
AP - Mon Nov 30, 3:26PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq stock market:
SPLS: 8.54 (-0.01), F: 12.17 (-0.01), CSC: 51.57 (-0.30), ORMP: 7.84 (-0.03), VALE: 5.42 (unch), MCUR: 1.45 (+0.03), ODP: 3.71 (+0.08)
Macrocure Ltd. Reports Changes to Senior Management and the Board of Directors
GlobeNewswire - Fri Nov 27, 12:05PM CST
Macrocure Ltd. ("Macrocure" or the "Company"
(NASDAQ:MCUR), today announced that as the Company continues to explore potential strategic alternatives, Tomer Kariv, a current Director on the Company's Board and CEO & Founder of Pontifax, will become Chairman of the Board replacing David Ben-Ami, current Chairman of the Company's Board of Directors, who will remain a member of Macrocure's Board of Directors. Mark Page, Chief Financial Officer, will be stepping down from his position at Macrocure by February 2016 to pursue other opportunities. Shai Lankry, current VP Finance and former CFO of Macrocure, will be assuming Mark's responsibilities. Dr. Michael Molyneaux, Chief Medical Officer, will also step down from his position in December. MCUR: 1.45 (+0.03)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Mon Nov 23, 10:33AM CST
NEW YORK, NY / ACCESSWIRE / November 23rd, 2015 / StockMarketLeader.com is an investor alert service that exclusively highlights public companies on the NASDAQ & NYSE with strong upside potential. We are committed to providing the best recommendations in the market on a short and long term basis. Receive our free trade alerts via text message (SMS) and/or email at www.StockMarketLeader.com. Today we are focusing on four companies to watch trading under $500M Market Cap that have been attracting major attention in the market.
SUNE: 0.34 (unch), MCUR: 1.45 (+0.03)
Macrocure Ltd. Reports Third Quarter 2015 Financial Results
GlobeNewswire - Tue Nov 17, 3:05PM CST
Macrocure Ltd. ("Macrocure" or the "Company"
(NASDAQ:MCUR), today provided a corporate update and reported financial results for the third quarter and nine months ended September 30, 2015. MCUR: 1.45 (+0.03)
Macrocure Ltd. Announces Results for Phase III Clinical Trial of CureXcell(R) in Diabetic Foot Ulcers and Provides Corporate Update
GlobeNewswire - Tue Oct 27, 4:20PM CDT
Macrocure Ltd. ("Macrocure" or the "Company"
(NASDAQ:MCUR), a clinical-stage biotechnology company focused on advancing its novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that results from a pivotal Phase 3 multicenter, randomized, double-blind, parallel-group, sham-controlled study (MC-102) of CureXcell(R) in the treatment of diabetic foot ulcers (DFUs) did not meet its primary endpoint. CureXcell, the Company's lead product candidate, did not show a statistically significant proportion of subjects with complete closure at 16 weeks and sustained complete closure for four additional weeks. In addition, CureXcell did not meet the secondary endpoints of the study. MCUR: 1.45 (+0.03)
Moving Average Crossover Alert: Macrocure (MCUR)
Zacks Equity Research - Zacks Investment Research - Mon Sep 21, 8:40AM CDT
Moving Average Crossover Alert: Macrocure (MCUR)
MCUR: 1.45 (+0.03)
Second Quarter Results at a Glance - Report on Macrocure Ltd.
PR Newswire - Wed Sep 16, 8:25AM CDT
ACI Association has initiated research coverage on Macrocure Ltd. (NASDAQ: MCUR). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
MCUR: 1.45 (+0.03)
Macrocure Ltd. Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell(R) in Venous Leg Ulcers
GlobeNewswire - Wed Aug 19, 5:40PM CDT
Macrocure Ltd. ("Macrocure" or the "Company"
(NASDAQ:MCUR), a clinical-stage biotechnology company focused on advancing its novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that a pre-specified, futility analysis conducted by the Data Safety Monitoring Board for CureXcell(R) - the Company's lead product candidate in its Phase 3 pivotal clinical study (MC-105) for venous leg ulcers (VLU) - determined that this study is not expected to meet its primary endpoint. MCUR: 1.45 (+0.03)
Macrocure Ltd. Provides Corporate Update and Reports Second Quarter 2015 Financial Results
GlobeNewswire - Tue Aug 04, 3:05PM CDT
--Company to Report VLU Futility Analysis Results in the Second Half of August 2015--
MCUR: 1.45 (+0.03)
Macrocure Ltd. Announces Second Quarter 2015 Financial Results Date and Conference Call
GlobeNewswire - Wed Jul 22, 7:01AM CDT
Macrocure Ltd. (NASDAQ:MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, will announce financial results for the second quarter ended June 30, 2015 after the close of the U.S. financial markets on Tuesday, August 4, 2015. An accompanying conference call to discuss the financial results and provide a business update will be held on Wednesday, August 5, 2015 at 9:00 am ET; 6:00 am PT; 4:00 pm Israel time.
MCUR: 1.45 (+0.03)
Macrocure (MCUR) Falls: Stock Goes Down 10% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 24, 7:41AM CDT
Macrocure fell nearly 10% in the last trading session, reversing its recent uptrend
GILD: 81.37 (-0.15), MCUR: 1.45 (+0.03)
Macrocure Ltd. to Present at the Jefferies 2015 Global Healthcare Conference
GlobeNewswire - Fri May 29, 7:00AM CDT
Macrocure Ltd. (Nasdaq:MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that at 10:30 AM ET on Thursday, June 4, 2015, Mr. Nissim Mashiach, Macrocure's President and Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference in New York City.
MCUR: 1.45 (+0.03)
